CONTACT US
Search
Immunotherapy designed
to combat cancer

IDM Pharma is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer.

We are currently developing two types of products designed to:

Destroy cancer cells by activating innate immunity
Prevent tumor recurrence by triggering a specific adaptive immune response

learn more >>

 
Latest News

11/18/2008

IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)

11/13/2008

IDM Pharma Reports Third Quarter Financial Results

09/26/2008

IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
 

News Archive >>